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ABSTRACT
Quantification of tumor necrosis in cancer patients is of diagnostic value as the 
amount of necrosis is correlated with disease prognosis and it could also be used to 
predict early efficacy of anti-cancer treatments. In the present study, we identified 
two near infrared fluorescent (NIRF) carboxylated cyanines, HQ5 and IRDye 800CW 
(800CW), which possess strong necrosis avidity. In vitro studies showed that both 
dyes selectively bind to cytoplasmic proteins of dead cells that have lost membrane 
integrity. Affinity for cytoplasmic proteins was confirmed using quantitative structure 
activity relations modeling. In vivo results, using NIRF and optoacoustic imaging, 
confirmed the necrosis avid properties of HQ5 and 800CW in a mouse 4T1 breast 
cancer tumor model of spontaneous necrosis. Finally, in a mouse EL4 lymphoma tumor 
model, already 24 h post chemotherapy, a significant increase in 800CW fluorescence 
intensity was observed in treated compared to untreated tumors. In conclusion, we 
show, for the first time, that the NIRF carboxylated cyanines HQ5 and 800CW possess 
strong necrosis avid properties in vitro and in vivo. When translated to the clinic, 
these dyes may be used for diagnostic or prognostic purposes and for monitoring 
in vivo tumor response early after the start of treatment.
INTRODUCTION
Cell death by necrosis merely occurs under 
pathological conditions, as a result of physiochemical 
damage or sudden metabolic failure and is involved in 
cancer development and treatment [1, 2]. The amount 
of tissue necrosis is of diagnostic value in many cancer 
types, since a high degree of necrosis is an indicator of 
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rapid and aggressive tumor growth and is often correlated 
with poor prognosis [3–10]. Moreover, necrosis can also 
be induced by injury caused to tumor tissue by anti-cancer 
treatments. Finally, therapeutic approaches that initially 
induce apoptotic cell death often result in secondary 
necrosis, as a natural outcome of the complete apoptotic 
program [11]. Accurate quantification of the amount 
of tissue necrosis has great potential for pre- clinical 
and clinical applications, especially in monitoring anti-
cancer efficacy at an early stage of treatment instead of 
at the end of therapy. However, the existing modalities 
and methods as for example standardized uptake values 
(SUVs) of FDG-PET, determination of tumor markers 
or of specific tumor mRNAs all lack the accuracy for a 
broad and routine application [12, 13]. Therefore, the long 
lag- time in determining therapy outcome causes loss of 
valuable treatment time in non-responding patients that 
will receive expensive treatment and are unnecessarily 
exposed to side effects. Early evaluation of the therapy 
efficacy would therefore facilitate the growing call for 
individualized cancer treatment, allowing the clinician to 
adjust the therapy based on tumor response, resulting in 
higher survival rates and cost-efficacy [1, 2].
In vitro, cell necrosis is often measured using dyes 
such as Eosin, Propidium Iodide (PI), TO-PRO-3 and 
Trypan Blue, which enter necrotic cells upon loss of 
membrane integrity and cannot permeate living cells. PI 
and the cyanine TO-PRO-3 subsequently intercalate into 
DNA [14–16] rendering them potentially mutagenic, which 
has hampered their clinical use. Perfetto et al. showed 
that amine-reactive cyanines could also be employed 
to discriminate between living and dead cells in vitro 
[17, 18]. The amine-reactive group on such cyanines 
can covalently interact with free amino moieties that are 
available on every protein. Because these amine-reactive 
compounds are incapable of passing intact cell membranes, 
only extracellular membrane proteins of living cells are 
labeled. However, as soon as cells lose their membrane 
integrity, cytoplasmic proteins become available for dye 
binding, leading to an accumulation of these agents in dead 
cells. Though, this principle cannot be employed in vivo, 
as immediately after injection, these reactive cyanines will 
non-specifically interact with all proteins accessible.
In vivo, MRI in combination with non-specific 
contrast agents, such as Dotarem, have been employed to 
visualize necrosis. However, with this procedure it was 
impossible to reliably distinguish healthy from necrotic 
tissue or neoplastic growth [19]. Consequently, the focus 
shifted towards the development of compounds that could 
selectively target necrotic tissues. Already in 1988, Epstein 
and colleagues developed monoclonal antibodies against 
nuclear antigens, allowing specific targeting of necrotic 
tissue present in solid tumors [20]. However, the use of 
antibodies is limited due to their size, resulting in limited 
tissue penetration, as well as the induction of unwanted 
immune responses [21].
Necrosis avid contrast agents (NACAs) are 
another class of compounds that specifically accumulate 
in necrotic tissue, these are categorized in porphyrin 
and non-porphyrin-based compounds. NACAs, such 
as the well-known compound hypericin, are assumed 
to specifically bind proteins, peptides and nucleotides 
that become available upon loss of cell membrane 
integrity [22, 23]. However, most of these compounds 
have poor solubility, high tendency to aggregate, are 
photo-toxic and lack specificity, which are the main 
reasons why there are currently no clinically approved 
NACAs available [23, 24]. Therefore, there is an unmet 
need for non-toxic, small-molecule based probes that can 
target necrosis with high specificity for diagnostic imaging 
and treatment follow-up.
In the present study, using several in vitro, cell 
death, assays, we identified the near infrared fluorescent 
(NIRF) carboxylated cyanines, HQ5 and 800CW as new 
non-toxic water soluble NACAs. These NACAs bind to 
intracellular cytoplasmic proteins of cells that have lost 
membrane integrity. We employed quantitative structure 
activity relations (QSAR) modelling to predict the overall 
trajectory of these dyes to their cellular localization sites. 
In contrast to amine-reactive or maleimide containing 
cyanines, used for protein labeling, carboxylated cyanines 
cannot covalently interact and are therefore indicated as 
non-reactive. Next to in vitro studies, we also characterized 
the necrosis avid properties of HQ5 and 800CW in an 
in vivo 4T1 mouse breast cancer model of spontaneous 
tumor necrosis and in an EL4 murine lymphoma model 
in which cell death was induced by chemotherapy. In 
these animal models, due to their small size, whole 
body imaging using NIRF imaging, or multi-spectral 
optoacoustic (OA) imaging, is well suited as a light 
penetration depth of several cm can be obtained in this 
part of the spectrum [25]. The actions of the cyanines were 
compared to those of the blood pool agent 800CW-PEG.
RESULTS
QSAR modelling
Figure 1a shows estimates of the most widely 
used numerical structure parameters, amphiphilicity 
index (AI), conjugated bond number (CBN), lipophilicity 
(logP) and charge (Z), applied to QSAR modelling of the 
carboxylated cyanines HQ5 and 800CW.
In vitro characterization of necrosis 
avid cyanines
Using a newly developed in vitro cell death assay, 
based on local killing of cells by freezing [26], we 
identified the carboxylated cyanines HQ5 and 800CW 
to exhibit strong necrosis avid and imaging properties. 
Figure 1b shows a schematic representation of the central, 
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dry ice induced, area of dead 4T1-luc2 cells (D) and 
the rim of living cells (L) in the periphery. Moreover, 
bioluminescent imaging (BLI) measurements, indicated 
that no bioluminescent signals were obtained from the dead 
cells in the center of the well while the surrounding living 
cells produced strong signals. In contrast, HQ5 or 800CW 
incubated wells showed a strong fluorescent signal in the 
area of dead cells, but not in the area of living cells. The 
non-specific contrast agent 800CW-PEG, however, showed 
minimal affinity for dead cells.
The results obtained from the dry ice assay were 
confirmed by FACS analysis (Figure 1c). 4T1-luc2 cells 
which were killed by the cytotoxic agents gambogic acid 
(GA) or Staurosporine (Sta) stained highly positive for 
HQ5 and 800CW, this in contrast to living cells. Moreover, 
our FACS experiments showed that the commercially 
available NIRF imaging probes 800CW-2DG and 800CW-
EGF in which 2-Deoxyglucose (2-DG) or epidermal 
growth factor (EGF) are conjugated to the side chains of 
800CW, also specifically accumulated in dead 4T1-luc2 
cells However, the non-specific contrast agent 800CW-
PEG did not accumulate in dead cells.
Figure 2a depicts a confocal microscopic image 
of a GA treated 4T1-luc2 cell culture stained with 
HQ5, Annexin V-FITC (AVF) and PI. The bright-field 
(BF) image shows the morphology of GA treated cells 
undergoing cell death. Most cells stained AVF positive and 
a few were positive for HQ5 and PI. The HQ5 positively 
Figure 1: Physicochemical characteristics and in vitro examination of the necrotic avid properties of the near infrared 
fluorophores (NIRF) HQ5 and 800CW. a. λabs = absorbance wavelength; λem = emission wavelength; Mw = molecular weight; 
AI = amphiphilic index; CBN = conjugated bond number; logP = log octanol-water partition coefficient; Z = electric charge. b. In the dry 
ice cell death assay an area of necrotic cells was induced in the center of a confluent monolayer of 4T1-luc2 murine breast cancer cells 
by applying dry ice for 15 sec to the underside of a culture well. Cells in the periphery of the culture well remained alive (schematically 
represented as, D = dead cells, L = living cells). Cell viability was confirmed by bioluminescent imaging (BLI). After 15 min incubation of 
the cells with HQ5 or 800CW and subsequent washing, a strong fluorescent signal was obtained from the area of dead cells. The 800CW-
PEG signal was almost absent both in the areas of living and dead cells. c. FACS analyses performed with viable 4T1-luc2 cells and 4T1-
luc2 cells treated with GA (4 uM) or Sta 3 uM) treatment, followed by staining with HQ5 or 800CW. The fluorescence intensity of HQ5 or 
800CW stained dead cells was significantly increased compared to that of viable cells. FACS analyses were also performed with viable 
and GA treated cells, subsequently stained with 800CW-EGF, 800CW-2DG and 800CW-PEG. The fluorescence intensity of both 800CW-
EGF and 800CW-2DG, in dead cells, was increased compared to viable cells. Using 800CW-PEG, there was no detectable difference in 
fluorescence intensity between viable, dead and unstained cells.
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stained cells coincided with PI nuclear staining and not 
with AVF phosphatidylserine (PS) staining, as visualized 
in the merged image. The intracellular distribution of 
HQ5, PI and AVF staining in a single necrotic 4T1-luc2 
cell is shown in Figure 2b. PI selectively stained the cell 
nucleus whereas AVF membrane staining was spread 
unevenly over the entire cell surface leaving the nucleus 
unstained. The uneven distribution of the stain may be 
explained by the loss of membrane integrity. HQ5 showed 
a more uniform granular staining pattern and did not co-
localize with the nuclear stain PI or AVF. Furthermore, 
Figure 2c–2d shows that the granular HQ5 staining to a 
great extent co-localizes with Mito-tracker (mitochondria) 
but not with Lyso-tracker (lysosomes). Moreover, HQ5 
also reveals a unique perinuclear staining.
Confocal microscopy could not be performed using 
800CW as our system is not suitable for the detection of 
800 nm fluorescence.
Specific cyanine affinity towards membrane and 
cytoplasmatic proteins was examined on SDS-PAGE using 
isolated membrane- and cytoplasmic protein fractions of 
4T1-luc2 cells. As shown in Figure 3a, HQ5 and 800CW 
strongly stained several protein bands in the cytoplasmatic 
fraction, but not in the membrane fraction. There was 
Figure 2: Confocal microscopic images of the localization of HQ5 in gambogic acid treated 4T1-luc2 cells. a. The bright-
field view (BF) image shows the morphology of GA treated cells undergoing cell death. After treatment with GA, cells were stained with 
HQ5 (red), AVF (green) and PI (blue). A large number of cells stained positive for AVF. The merged image depicts a fluorescence overlay 
of HQ5, AVF and PI staining, indicating that cells stained with HQ5 were also positive for PI. b. At the level of a single necrotic cell it 
was shown that HQ5, appearing as a granular cytoplasmatic staining, did not co-localize with membrane AVF nor with PI nuclear staining. 
c–d. The granular HQ5 staining was further shown to have a great extent colocalization with Mitotracker (Mito) but not with Lysotracker 
(Lyso) in GA treated 4T1-luc2 cells. The bar represents 20 μm.
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some overlap in the staining pattern of the two dyes. 
Coomassie blue staining indicated that proteins were 
abundantly present in both fractions.
Furthermore, also affinity of the cyanines towards 
serum albumin was examined using SDS-PAGE analysis. 
As depicted in Figure 3b, HQ5 shows a stronger dose-
dependent binding to BSA compared to 800CW, although 
binding only occurred at micromolar concentrations
Animal model with tumor necrosis
The necrosis avid properties of the cyanines were 
evaluated in an animal model of 4T1-luc2 breast tumors, 
which, during growth, spontaneously develop a necrotic 
core. As shown in Figure 4a, the BLI signal obtained from 
these tumors has a lower intensity in the center compared 
to the periphery of the tumor, which is indicative of the 
presence of a necrotic core. As expected, FLI of the 
cyanine HQ5 showed strong accumulation of fluorescence 
in the necrotic center of the tumor.
Localization of HQ5 fluorescence in the necrotic 
core of the tumor was confirmed in 3D reconstructions 
of cryo-sections (Figure 4b) and showed co-localization 
with TUNEL staining in parallel paraffin tumor sections 
(Figure 4c). As shown in Figure 4d, 800CW and bio-
conjugated receptor targeting probes 800CW-2DG and 
800CW-EGF also strongly accumulated in the necrotic 
areas of tumors, indicated by a co-localization with 
TUNEL staining. In contrast, 800CW-PEG did not 
co-localize with TUNEL staining and most of its 
fluorescence signal was localized in the tumor periphery.
Furthermore, we employed 3D Multi-Spectral 
Optoacoustic Tomography (MSOT) imaging to visualize 
the location of HQ5 in the tumor in vivo. As shown in 
Figure 5, the HQ5 OA signal co-localized with the 
deoxygenated haemoglobin signal present in the center of 
the tumor and not with the oxygenated haemoglobin signal 
present in the viable rim of the tumor, confirming necrotic 
core localization.
Monitoring early therapeutic response in tumors
We investigated early therapeutic responses in 
tumors treated with a combination of the chemotherapeutic 
Figure 3: SDS-PAGE analyses of HQ5 and 800CW protein binding. a. SDS-PAGE gel electropherogram of cytoplasmatic- 
and membrane fractions of 4T1-luc2 cell lysate, incubated with HQ5 or 800CW. Protein binding of HQ5 and 800CW was observed in 
the cytoplasmic but not in the membrane fraction. Coomassie blue staining confirmed the presence of proteins in both fractions. HQ5 and 
800CW staining showed a different pattern, albeit with some common features. b. Binding of HQ5 or 800CW, at different concentrations 
(0.1, 0.5 and 2 μM), to bovine serum albumin (BSA).
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agents Cyclophosphamide (Cy) and Etoposide (Et) in 
EL4-CBG99-luc lymphoma bearing mice. For this, 
control tumor bearing mice and mice treated with 
Cy/Et were injected with 800CW 24 h after chemotherapy. 
After another 24 h, fluorescence intensity of the 
tumors was measured. We observed a 2.4-fold higher 
fluorescence intensity in the tumors of chemo treated mice 
compared to those of untreated animals (p < 0.001). Vice 
versa, the mean BLI intensity of untreated tumors was 
2.8-fold higher than that of chemo treated tumors (p < 0.05) 
(Figure 6a–6b). Histological examination of the tumors 
showed a large area of TUNEL positive tissue in the tumors 
Figure 4: In vivo and ex vivo imaging of spontaneous 4T1-luc2 tumor necrosis with HQ5, 800CW, 800CW-EGF, 
800CW-2DG and, 800CW-PEG. a. Representative in vivo whole body BLI and FLI images of a 4T1-luc2 tumor injected with HQ5. 
The BLI signal originated from the periphery of the tumor (red ring), whereas the HQ5 FLI signal mainly originated from the necrotic 
core (red spot). b. 3D reconstruction of the localization of HQ5 in a tumor using an automated fluorescence camera mounted on a cryo-
microtome. c. Images of a HQ5 and corresponding TUNEL stained tumor section. d. Images of a 800CW, 800CW-2DG, 800CW-EGF 
and a 800CW-PEG and their corresponding TUNEL stained tumor sections. In contrast to HQ5, 800CW, 800CW-2DG and 800CW-EGF, 
800CW-PEG did not co-localize with TUNEL staining.
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treated (Figure 6c) with chemotherapy which co localized 
with 800CW staining, whereas, no TUNEL or 800CW 
positive tissue was present in control tumors (Figure 6d).
DISCUSSION
Reagents that can monitor necrosis in vivo have 
potential diagnostic and prognostic value in staging 
of cancer as well as for monitoring early efficacy of 
anti-cancer therapies [1, 27]. Compared to apoptosis, 
relatively few studies have addressed the possible role 
of necrosis as a biomarker for clinical applications. As 
a result, clinical probes that specifically image or target 
necrosis are currently unavailable. Consequently, we 
present two NIRF carboxylated cyanines that display 
necrosis avidity in vitro and in vivo. Our dry ice cell death 
Figure 5: In vivo opto-acoustic imaging of necrosis of spontaneous 4T1-luc2 tumor necrosis with HQ5. MSOT 
measurements showing the single wavelength anatomical image and unmixed signals of oxygenized haemoglobin (oxi-Hb), deoxygenized 
haemoglobin (deoxi-Hb) and HQ5. Detail of HQ5 targeting of the necrotic core in the center of the tumor.
Figure 6: Monitoring anti-tumor efficacy in a EL4-CBG99-luc lymphoma mouse model of chemotherapy.  
a. Representative whole body FLI images of tumor bearing mice treated with a combination of CTX and ETO and 24 hr later injected 
with 800CW. After another 24 h, in vivo whole body and ex vivo tumor FLI and BLI images were acquired and signal intensities were 
quantified. b. The BLI signals obtained from the treated animals were significantly lower as compared to those of the untreated controls 
(*p < 0.05). In contrast, the 800CW signals from the treated animals were significantly higher as compared to those of the untreated controls 
(***p < 0.001). c–d. Images of 800CW containing and a TUNEL stained tumor section of an (c) untreated tumor and a (d) treated tumor. 
The fluorescent signal obtained from a section of a treated tumor co-localized with TUNEL staining of the same section. Negligible 800CW 
fluorescence and TUNEL staining was observed in the untreated tumor. T = treated; U = Untreated.
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assay showed a selective staining of dead cells using the 
carboxylated cyanines HQ5 and 800CW. However, no 
dead cell staining was observed with the macromolecule, 
800CW-PEG (25-60 kDa). Nevertheless, the smaller 
800CW-conjugated probes, 800CW-EGF (6 kDa) and 
800CW-2DG (1 kDa), also selectively stained dead cells. 
The results obtained in the dry-ice assay were confirmed 
by FACS analysis. The difference in necrosis avidity 
between 800CW and its PEG conjugated form might be 
due to the relatively large size of PEG which may cause 
steric hindrance, as 800CW is maximally 4% of the mass 
of the conjugate. In line, de Boer et. al. recently showed 
that macromolecule cetuximab-IR Dye 800CW was also 
unable to accumulate in tumor necrosis [28]. The binding 
to dead cells of the carboxylate forms of 800CW and HQ5 
might be unexpected since these compounds, in contrast 
to the NHS-ester and maleimide forms, do not contain a 
reactive group and mainly serve as “dye-only” control to 
examine potential retention of the compound. In addition, 
for 800CW it has been shown that after i.v. injection it 
does not retain in the body and is rapidly cleared via the 
kidneys [29].
Confocal microscopy showed no uptake of any 
stain in living cells. Nevertheless, after GA treatment 
we observed HQ5 staining coincided with PI but not 
with AVF staining. As PI selectively targets cells that 
have lost membrane integrity, this characteristic is most 
likely also involved in the dead cell targeting of HQ5. 
This indicates that HQ5 does not stain apoptotic cells but 
specifically targets necrotic cells. On a single cell level 
HQ5 staining did not co-localize with either AVF or PI 
staining and the granular HQ5 staining pattern appeared 
to be cytoplasmic. The cellular localization of 800CW 
could not be examined due to the absence of specific 800 
nm microscope settings. We confirmed the cytoplasmatic 
protein binding of our cyanines by SDS-PAGE analyses 
using isolated cell membrane and cytoplasmic protein 
fractions of 4T1-luc2 cells. These fractions were 
incubated with each dye and we observed that both bound 
to cytoplasmic and not to the membrane protein fractions. 
The pattern of protein binding of HQ5 and 800CW to 
cytoplasmic proteins partly overlapped and also showed 
preference for a different subset of proteins. This is most 
likely due to the different physical-chemical properties of 
these compounds.
Using a QSAR model [30, 31], which is based on 
the chemical characteristics of HQ5 and 800CW, the 
expected cellular localization was further explored. The 
selective accumulation of these dyes in dead cells requires 
consideration of both dye and cell properties; the former 
being summarized in Figure 1. The major species of both 
HQ5 and 800CW under physiological conditions are 
anionic (Z values of −1 and −4 respectively). Moreover, 
both dyes have conjugated systems of moderate size 
(CBN values of 34 and 31). Consequently, the QSAR 
model predicts both dyes will bind to proteins, albeit 
not extremely strongly, affinity being due both to ionic 
attractions with cationic protonated amines and to various 
non-ionic interactions (van der Waals forces). However, 
in other respects the dyes differ markedly. Whilst 
800CW is extremely hydrophilic (logP = −9.4) and lacks 
amphiphilicity (AI = 0), HQ5 is lipophilic and extremely 
amphiphilic (logP = 5.0 and AI = 12.5). Necrotic cells 
have two characteristic features, which are significant 
in this context. Their membranes, including those of 
the plasmalemma and mitochondria, are permeabilized, 
permitting the passage of impermeable dyes [32, 33]. 
As a result, the mitochondrial hydrophobic proteins are 
more easily accessed by dyes entering the necrotic cell. 
Moreover, protein denaturation will have increased the 
number of protein molecules with surface hydrophobic 
domains [34].
The hydrophilic character of 800CW renders it 
membrane impermeable [31] and so it can only enter 
permeabilised cells. Once within them, its accumulation 
will be favored by the enhanced dye-binding commonly 
found with denatured proteins [35]. As this dye is not 
amphiphilic, is does not bind significantly to serum 
albumin. HO5, however, is a lipophilic dye which based 
on our calculations could possibly enter cells by passive 
diffusion [31]. The reason that we do not find this in our 
in vitro assay and confocal analysis is most probably due 
to the fact that HQ5 is very amphiphilic and will bind to 
serum albumin. It has been shown that amphiphilicity is 
correlated with serum albumin affinity [31, 36]. Binding 
to serum albumin of HQ5 was confirmed by us using 
SDS-PAGE analysis. Once the cells have lost membrane 
integrity, HQ5 bound to albumin will enter the cells 
and will bind to proteins with hydrophobic domains, 
such as those common in mitochondria, or those which 
are denatured [37]. This is in line with the confocal 
microscopy data showing that HQ5 for a large part 
co-localizes with Mitotracker. From the QSAR model it 
is clear that, although HQ5 and 800CW have different 
chemical characteristics, both can bind to proteins but 
probably using different mechanisms. This is also reflected 
in the difference in binding patterns of the two dyes on 
SDS-PAGE, showing that they target similar and partly 
different cytoplasmic proteins. Further detailed studies are 
needed to elucidate the exact mechanism of binding of the 
dyes to necrotic cells.
Dyes with large conjugated systems (CBN > 40), 
but lacking amphiphilicity, such as Coomassie Blue and 
Evans Blue, are predicted by the QSAR model to bind 
strongly to all proteins [31]. Such dyes are therefore not 
expected to show selective uptake into necrotic cells, but 
will bind to whatever proteins are first contacted.
The question that remains is if, in vivo, 800CW 
and HQ5 specifically target necrotic tissues or that 
these compounds non-specifically localize in and 
around necrotic sites because they comprise blood pool 
characteristics? For example, previous studies indicated 
that blood pool contrast agents can be employed to 
indicate tissue injury, due to their passive leakage from 
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blood vessels at sites of tissue damage. In addition, blood 
pool agents are employed to detect tumors because of 
their ability to accumulate in tumor tissue, as a result 
of a process known as the enhanced permeability and 
retention (EPR) effect [38]. This process is characterized 
by the ability of macromolecules (>20 kDa), or small 
molecules bound to serum albumin, to accumulate in 
tumors as a result of their passive leakage from abnormal 
tumor vasculature. In contrast, small molecules (<20 kDa), 
which possess no affinity for blood proteins, do not retain 
and rapidly penetrate the interstitial space of tumors and 
subsequently diffuse freely back into the blood pool or 
the lymphatic system. Therefore, the increased retention 
of blood pool agents at or in the vicinity of tissue damage 
sites or in tumors is not due to a specific interaction 
with necrotic tissue, but is merely the result of reduced 
diffusion velocity of large molecules out of the tissue 
compartment.
Previous studies and our study show that 800CW 
possesses very low affinity for blood proteins and 
consequently rapidly extravasates after i.v. injection 
[39]. This indicates that the small molecule 800CW is 
not a blood pool agent and, therefore, will retain in tissue 
because of a specific binding to intracellular proteins 
of necrotic cells. The in vivo specificity of 800CW for 
necrotic tissues is strengthened by the observation that this 
compound strongly co-localizes with TUNEL staining, 
a feature that is not observed with the blood pool agent 
800CW-PEG. Similar to 800CW, HQ5 also shows a strong 
co-localization with TUNEL staining in necrotic areas in 
tumors. However, in contrast to 800CW, HQ5 can bind to 
serum albumin and thus potentially serves as blood pool 
agent. Similarly, the photosensitizer Hypericin, which 
is currently under pre-clinical investigation because of 
its necrosis avid properties, also possesses affinity for 
albumin [40]. In contrast, the well-known blood pool 
agent Evans Blue, which also strongly binds to serum 
albumin, has been shown to target the viable rim of tumors 
rather than the necrotic core [41]. Moreover, based on 
the observation that of the albumin binding compounds 
Gadophrin-2 and MP2269, only the first possessed NACA 
properties Ni et al. [23] stated that necrosis-avidity is an 
outstanding feature beyond the general pharmacological 
process of albumin-binding mediated drug transportation. 
Combined, it might be concluded that the role of blood 
protein binding in the mode of action of this particular 
group of NACAs needs, to be established.
In our 4T1-luc2 tumor necrosis model, HQ5 and 
800CW showed co-localization with TUNEL staining, and 
the same was true for the 800CW-EGF and 800CW-2DG 
conjugated probes and not for 800CW-PEG. Therefore, it 
is important to note that 800CW-EGF and 800CW-2DG, 
that are specifically designed and have been extensively 
used to target the EGF receptor (EGFR) and the Glucose 
receptor-1 (GLUT) [42, 43], also have strong necrosis 
avidity due to the presence of CW800 which can direct 
these probes towards necrotic cells. This new finding 
has to be taken into consideration when interpreting 
experimental results obtained with 800CW-EGF and 
800CW-2DG [29, 44–46].
The necrosis avidity of HQ5 and 800CW was further 
investigated in a well-known model of chemotherapy. 
We showed that 800CW could be used to monitor early 
treatment efficacy. This feature is of great significance 
since in current clinical practice the efficacy of anti-
cancer treatment can only reliable be established late 
during treatment or after completion of the treatment. 
Therefore, currently non-responding patients receive an 
expensive treatment and are unnecessarily exposed to side 
effects [1, 2]. Finally, it is worth mentioning some of the 
limitations of the present study, which include the use of 
athymic mice, the use of transplanted and not spontaneous 
tumors and the usage of only one type of anti-cancer 
treatment, namely chemotherapy.
Future perspectives and clinical relevance
OA imaging, a technique in which a pulsating light 
signal is transformed into an ultrasound wave, provides 
much deeper tissue penetration (approximately 5 cm) and 
higher resolution than other optical imaging modalities 
currently available. This technology can revolutionize 
medical imaging in clinical practice. With the development 
of a handheld MSOT scanner, with applications in breast 
and melanoma imaging, the clinical translation of OA 
imaging is already materialized and may also ease the 
translation of our necrosis probes to the clinic especially 
since we have shown that HQ5 can be detected using 
MSOT [47–50].
However, for detection of tumors deep within the 
body, when measurements beyond the maximal optical 
or OA penetration depth are required, the dyes have to 
be radiolabeled in order to allow their visualization 
with standard clinical imaging modalities like SPECT 
or PET. Our preliminary results show that radiolabeling 
of a structural analogue of HQ5 with Indium-111, using 
the chelate DTPA is feasible and that this probe still 
specifically accumulates in necrotic cells in vitro and in 
necrotic cores of tumors (unpublished data). Moreover, 
from an economical point of view it is worth to mention 
that the production costs of the cyanines, especially when 
synthesized in bulk amounts are low and that the rates for 
radio labeling and subsequent SPECT/PET scanning will 
be comparable to those of other clinically used SPECT/
PET probes.
The concept of employing tissue necrosis, as a 
biomarker for diagnostic and prognostic purposes of 
disease, is not new. With the objective to target and 
image necrotic tissue, already back in 1988 Epstein and 
colleagues developed several so called TNT antibodies [20] 
and more recently Ni and colleagues [22, 40, 51, 52] 
reported on the specific necrosis avid properties of the 
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photosensitizer Hypericin in small animals. However, 
both compounds were examined not just for their potential 
as contrast agents, but also for their possible usage in 
cancer treatment by coupling of Iodine-131 used for local 
radionuclide therapy. In this way, when the necrosis avid 
agent has accumulated in the necrotic core of the tumor, the 
cancer is selectively irradiated and killed from the inside. 
After showing proof of concept, in animal studies [53], the 
TNT antibodies even reached clinical phase I and II studies 
[54]. However, for both TNT antibodies and Hypericin, 
full clinical translation is hampered because of increased 
concern about adverse effects and other drawbacks based 
on their physical-chemical properties [54, 55]. No such 
concerns are expected with the employment of the NIRF 
cyanines examined in this study. NIRF cyanines are 
successfully used already for more than a decennium for 
experimental and clinical experimental purposes including 
fluorescence image guided surgery without serious side 
effects [56]. In addition, toxicity studies by Marshall and 
colleagues, showed that 800CW carboxylate administrated 
as a single intravenous or intradermal dose of 20 mg/kg, 
which is about 100-fold above the maximum dose utilized 
in our experiments, did not result in any pathological 
evidence of toxicity in rats [29]. Therefore, our necrosis 
avid carboxylated NIRF dyes can potentially be used 
clinically to image necrotic tissue for diagnostic and 
prognostic purposes, to detect treatment response in tumors 
and for drug delivery.
In conclusion, we have demonstrated that the 
carboxylated cyanines 800CW and HQ5, as well as 800CW-
2DG and 800CW-EGF, possess strong necrosis avid 
properties. The molecular mechanism of necrosis avidity 
involves targeting of cytoplasmic proteins after loss of 
cell membrane integrity. Using NIRF imaging in different 
mouse models of cancer, we showed that these dyes can be 
applied to detect spontaneous tumor necrosis, which is of 
diagnostic and prognostic value. Moreover, we showed that 
they can be utilized to monitor early treatment responses in 
tumors after anti-cancer therapy and potentially they can 
also be used for drug delivery. Therefore, when translated 
to the clinic, these compounds might become of great value 
in cancer diagnostics and treatment.
MATERIALS AND METHODS
QSAR modelling
Estimation of the structure parameters for 
carboxylated HQ5 and IRDye 800CW (800CW) and the 
integration of the parameters with appropriate QSAR 
models was carried out as detailed elsewhere [30, 31].
Cyanines
HQ5 carboxylate was obtained from Ilumicare 
BV (Rotterdam, The Netherlands). The dyes 800CW, 
800CW-2-Deoxyglucose (800CW-2DG), 800CW-epidermal 
growth factor (800CW-EGF) and 800CW-polyethylene 
glycol (800CW-PEG) were obtained from LI-COR 
Biosciences.
Cells and culture conditions
4T1-luc2 murine mammary cancer cells 
(PerkinElmer) were cultured in complete RPMI-
1640 medium (Life Technologies, Inc.). EL4 murine 
lymphoma cells were cultured in complete Iscove’s 
Modified Dulbecco’s Medium (Life Technologies). Cells 
were transduced with a lentivirus for the expression of 
CBG99 luciferase under the control of the constitutive 
promoter PGK as described previously to create 
EL4-CBG99-luc [57].
Dry ice dead cell assay
In vitro, cell death was studied using a cryo-induced 
cell death assay, which detailed procedures have been 
described previously [26]. Briefly, a bar of dry ice was 
applied to the underside of the culture well confluent with 
4T1-luc2 cells for 15 sec. Subsequently, the cells were 
incubated with HQ5, 800CW or 800CW-PEG, respectively 
(100 nM, 15 min, room temperature (RT), in the dark). 
After gentle washing with PBS, the samples were scanned 
for fluorescence imaging (FLI) using an Odyssey Infrared 
Imager 9120 (LI-COR). For bioluminescence imaging 
(BLI), D-luciferin solution (25 μg/μl; SynChem Inc.) was 
added for 10 min incubation. BLI measurements were 
then acquired using an IVIS Spectrum imaging system 
(PerkinElmer).
FACS analyses
The detailed procedures for flow cytometry of cells 
after inducing cell death have been described previously 
[26]. Briefly, 4T1-luc2 cells were incubated in the 
presence or absence of gambogic acid (GA, 4 μM, 24 h, 
Calbiochem) or Staurosporine (Sta, 3 μM, 24 h, Sigma-
Aldrich). Cells were then collected and re-suspended in 
100 μl PBS. The cell suspensions were incubated in the 
dark for 15 min at RT with one of the cyanines (200 nM). 
Alternatively, cells were stained with the commercially 
available cell death probes AVF and PI (PromoKine) 
in accordance with the manufacturer’s protocols. Flow 
cytometry was performed using a BD LSR II or Canto II 
Flow Cytometer (BD Biosciences). The data was analyzed 
using FlowJo software.
Confocal microscopy
4T1-luc2 cells were cultured in a glass bottomed 
culture dish (MatTek Corp.) until 80% confluent. Cell 
death was induced by incubation with GA (3 μM, 1 h). 
Subsequently, the cells were washed gently with PBS and 
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incubated in the presence of 80 nM HQ5 in the dark for 
15 min at RT. AVF and PI were used in accordance with the 
manufacturer’s protocols. Afterwards, samples were imaged 
using a Leica TCS SP5 confocal microscope (Leica).
SDS-PAGE analyses
Cytoplasmic and membrane protein samples of 
4T1-luc2 cells were prepared using a subcellular protein 
fractionation kit (Thermo Scientific) according to the 
manufacturer’s protocol. Samples of protein extracts 
(2 μg per lane) were incubated with either HQ5 or 800CW 
(1 μM) for 15 min at RT in the dark. For Bovine serum 
albumin (BSA) commercial preparations of BSA (5 μg per 
lane, Life Technologies) were incubate with either HQ5 
or 800CW (0.1, 0.5 and 2 μM, respectively) for 15 min 
at RT in the dark. Subsequently, samples were mixed 
with SDS-PAGE sample buffer without indicative blue 
dye and loaded onto reduced 12.5% SDS polyacrylamide 
gel. The precision plus protein marker (BIO-RAD) was 
loaded to one extra lane. After running SDS-PAGE, the gel 
was processed for FLI using the Odyssey Infrared Imager 
9120 scanner. Finally, protein samples were stained 
with Coomassie brilliant blue staining (BIO-RAD) and 
photographed.
Animals
Female athymic mice (BALB/c nu/nu, 6 weeks old) 
were acquired from Charles River Laboratories (L’Arbresle 
Cedex, France). All experimental procedures were 
performed under isoflurane gas anesthesia (3% induction, 
1.5–2% maintenance) in 70% pressurized air and 30% O2, 
unless stated differently. Animals were sacrificed by 
cervical dislocation at the end of the experimental period. 
The animals were housed per 4–5 animals in individually 
ventilated cages with ad libitum access to food and water. 
All animal experiments were assessed for animal health & 
ethics and approved by the Animal Welfare Committee of 
Leiden University Medical Center, the Netherlands. All 
mice received humane care and were kept in compliance 
with the Code of Practice Use of Laboratory Animals in 
Cancer Research (Inspectie W&V, July 1999).
Spontaneous tumor necrosis model
Mice (n = 5) received orthotopic inoculations of 
2 × 104 4T1-luc2 cells beneath the upper mammary fat 
pad. Trypan Blue (Sigma-Aldrich) exclusion was used to 
examine the viability of the tumor cells before injection. 
After three weeks, tumors were formed, containing a 
spontaneous necrotic core. Whole body BLI and FLI 
measurements were performed using the IVIS Spectrum, 
with either 10 min post D-luciferin (150 mg/kg) per 
intraperitoneal (i.p.) injection or 24 h post HQ5 (2 nmole 
per mouse) per i.v. injection.
3D fluorescent cryomicrotome imaging of a tumor 
was reconstructed according the previous published 
methods [58]. In brief, tumor samples were immersed 
in carboxymethylcellulose sodium solvent (Brunschwig 
Chemie, Amsterdam, The Netherlands) mixed with 5% 
Indian ink (Royal Talens, Apeldoorn, The Netherlands) 
and frozen for at least 24 hrs at −25°C. After each cut, 
tumor epi-illumination outline images were acquired 
at an excitation wavelength of 440 nm/20 nm (central 
wavelength and bandwidth) and an emission wavelength 
of 435 nm/25 nm, with 300 ms illumination time. Images 
of tumor fluorescence were acquired at an excitation 
wavelength of 640 nm/50 nm and an emission wavelength 
of 712 nm/75 nm, 5000 ms illumination. All tissue 
samples were imaged in one session with camera binning 
set at 2048 × 2048 pixel resolution, with a corresponding 
in-plane resolution of 17 μm. Prior to further analysis, 
images were converted to 8 bit grey scale.
MSOT imaging
A group (n = 3) of female athymic nude-Fox1nu 
mice was inoculated with 4T1 cells and subjected to 
MSOT measurements. MSOT measurements were 
performed using the inVision 256-TF system (iThera 
Medical GmbH, Munich, Germany) according to the 
protocol described previously [59, 60]. In brief, the mice 
were anesthetized and placed in supine position in the 
animal holder throughout the entire imaging process. 
Cross-sectional multispectral OA image datasets were 
acquired through the tumor at eight different wavelengths 
in the NIR window (690, 700, 710, 740, 760, 780, 800 
and 900 nm). MSOT datasets are reconstructed using the 
interpolated model-matrix inversion. Afterwards, linear 
spectral unmixing is applied to each set of multiwavelength 
images to resolve biodistribution of the different tissue 
chromophores and the contrast agent, i.e. oxygenized and 
deoxygenized haemoglobin and HQ5 [61].
Chemotherapy of murine lymphomas
Two randomized groups mice (n = 3) received 
a subcutaneous (s.c.) inoculation with 1 × 105 EL4-
CBG99-luc murine lymphoma cells on the upper 
back. 11 days after inoculation, the animals either 
received chemotherapy consisting of i.p. injection of a 
combination of cyclophosphamide (CTX, 100 mg/kg; 
Baxter BV, The Netherlands) and etoposide (ETO, 
70 mg/kg; Pharmachemie BV, The Netherlands) or 
remained untreated. After 24 h, all animals received 
an i.v. injection of 800CW (5 nmole per mouse). 
FLI measurements were performed another 24 h after 
injection using the IVIS spectrum. Whole body BLI 
measurements were performed, before and 24 h after 
injection of the chemotherapeutic agents, 10 min after i.p. 
administering D-luciferin (150 mg/kg). After FLI, all mice 
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were sacrificed and the tumors were surgically excised for 
ex vivo FLI and processed for histological analysis. Image 
analyses were performed using the Living Image software. 
For quantitative analysis, regions of interest (ROI) from 
acquired images were selected to cover the tumor regions. 
Statistical analysis of the average fluorescent radiant 
efficiency in ROIs was performed using a Student’s t-test.
Histopathology analysis
4T1-luc2 and EL4-CBG99-luc tumors were fixed in 
4% formaldehyde and embedded in paraffin. 5 μm sections 
were prepared and imaged for FLI using the Odyssey 
Infrared Imager 9120 scanner. Afterwards, the consecutive 
sections were subjected to TdT-mediated dUTP Nick-
End Labelling (TUNEL) staining (Promega) to validate 
accumulation of the NIRF probes in dying and dead cells.
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